← Back to Search

[18F]FP-R01-MG-F2 for Healthy Subjects

Phase < 1
Waitlist Available
Led By Andrei Iagaru
Research Sponsored by Sanjiv Sam Gambhir
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 hours after tracer injection
Awards & highlights

Study Summary

This trial is studying how well integrin alpha-v-beta [18F]-R01-MG-F2 Positron Emission Tomography/Computed Tomography (PET/CT) and Positron Emission Tomography-Magnetic Resonance Imaging (PET/MRI) work in finding and measuring response in patients with pancreatic cancer and healthy volunteers.

Eligible Conditions
  • Healthy Subjects
  • Pancreatic Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 hours after tracer injection
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 hours after tracer injection for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Biodistribution of [18F]FP-R01-MG-F2 (%ID/g)
Biodistribution of [18F]FP-R01-MG-F2 (SUV)
Dosimetry of [18F]FP-R01-MG-F2 (mSv/MBq)
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: pancreatic cancer patientsExperimental Treatment4 Interventions
Patients receive [18F]FP-R01-MG-F2 IV and undergo PET/CT or PET/MRI scan immediately after and at 60 and 120 minutes.
Group II: healthy patientsExperimental Treatment4 Interventions
Patients receive [18F]FP-R01-MG-F2 IV and undergo PET/CT or PET/MRI scan immediately after and at 60 and 120 minutes.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PET/MRI scan
2016
Completed Early Phase 1
~30
Computed Tomography
2017
Completed Phase 2
~2720
[18F]FP-R01-MG-F2
2016
Completed Early Phase 1
~30

Find a Location

Who is running the clinical trial?

Sanjiv Sam GambhirLead Sponsor
6 Previous Clinical Trials
69 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,654 Previous Clinical Trials
40,933,132 Total Patients Enrolled
Stanford UniversityLead Sponsor
2,386 Previous Clinical Trials
17,333,987 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
European Journal of Nuclear Medicine and Molecular ImagingJournal
Pilot-phase PET/CT Study Targeting Integrin Αvβ6 in Pancreatic Cancer Patients Using the Cystine-knot Peptide–based 18F-FP-R01-MG-F2
Nakamoto, Ryusuke, Valentina Ferri, Heying Duan, Negin Hatami, Mahima Goel, Jarrett Rosenberg, Richard Kimura, et al.. 2021. “Pilot-phase PET/CT Study Targeting Integrin Αvβ6 in Pancreatic Cancer Patients Using the Cystine-knot Peptide–based 18F-FP-R01-MG-F2”. European Journal of Nuclear Medicine and Molecular Imaging. Springer Science and Business Media LLC. doi:10.1007/s00259-021-05595-7.
clinicaltrials.govStudy
Integrin Alpha-v-Beta and [18F]-R01-MG-F2 PET/CT in Measuring Response in Patients With Pancreatic Cancer and Healthy Volunteers
Sanjiv Sam Gambhir 2016. "Integrin Alpha-v-Beta and [18F]-R01-MG-F2 PET/CT in Measuring Response in Patients With Pancreatic Cancer and Healthy Volunteers". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02683824.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top